TOSCARA Study: A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Na�ve to RoActemra/Actemra Treatment
Read time: 1 mins
Last updated:16th Dec 2013
This open-label, single-arm study will evaluate the efficacy and safety of subcutaneously administered RoActemra/Actemra (tocilizumab) in monotherapy and/or in combination with methotrexate and other non-biologic DMARDs in patients with active rheumatoid arthritis who are na�ve to RoActemra/Actemra. Patients will receive RoActemra/Actemra 162 mg subcutaneously weekly for 24 weeks. Patients who complete the core study achieving at least a moderate EULAR response at Week 24 may enter the extension phase and receive RoActemra/Actemra for a further 28 weeks at the most.
|Study start date||2013-12-16|